Back HIV Populations Women & HIV

Women & HIV

Gilead Submits Applications for FDA Approval of Elvitegravir and Cobicistat

On June 27 Gilead Sciences announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of its new integrase inhibitor, elvitegravir, for use in combination antiretroviral therapy for treatment-experienced adults with HIV. The following day the company also requested approval of its novel boosting agent cobicistat.alt

Read more:

Quad Pill Matches Atripla and Atazanavir for First-line HIV Treatment

Gilead's investigational Quad pill, a 4-in-1 coformulation containing the second-generation integrase inhibitor elvitegravir and a new boosting agent, performed as well as either the 3-in-1 Atripla coformulation or the popular protease inhibitor atazanavir (Reyataz) in Phase 3 studies, researchers reported in the June 30, 2012, issue of The Lancet.

alt

Read more:

Dapivirine Vaginal Ring HIV Prevention Trial Launched in Africa

The International Partnership for Microbicides (IPM) last week announced the start of large clinical trial testing whether a vaginal ring containing dapivirine can reduce women's risk of becoming infected with HIV.alt

Read more:

CDC Review Finds No Link Between Hormonal Contraception and HIV Risk

A data review by the U.S. Centers for Disease Control and Prevention (CDC) has failed to confirm a previously described association between injectable or oral hormonal contraceptives and increased likelihood of HIV infection or disease progression, researchers reported in the June 22, 2012, issue of Morbidity and Mortality Weekly Report.alt

Read more:

ASCO 2012: Breast Cancer Outcomes among HIV Positive Women

Women with HIV can do well on a variety of different types of treatment for breast cancer, but they are prone to infections and blood cell deficiencies and may benefit from adjunct therapies, researchers reported at the American Society of Clinical Oncology Annual Meeting (ASCO 2012) taking place this week in Chicago.

alt

Read more: